Fremanezumab for the prevention of chronic and episodic migraine

• Luana Lionetto ^[3] ; Fabiola Cipolla ^[1] ; Martina Guglielmetti ^[2] ; Paolo Martelletti ^[1]
  1. [1] Università de Roma La Sapienza

     Università de Roma La Sapienza

     Roma Capitale, Italia

     
  2. [2] University of Sassari

     University of Sassari

     Sassari, Italia

     
  3. [3] Analytical Laboratory, Clinical Biochemistry Unit, Sant’Andrea University Hospital, Via di Grottarossa 1035-1039, Sapienza, Rome, 00189, Italy

  Mostrar afiliaciones +
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 55, Nº. 4, 2019, págs. 265-276
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • On September 15, 2018, the U.S. Food and Drug Administration (FDA) approved subcutaneous fremanezumab, a calcitonin gene-related peptide (CGRP) monoclonal antibody, for the treatment of episodic and chronic migraine in adults, with two recommended dosages: 225 mg monthly or 675 mg every 3 months. On March 28, 2019, the European Commission granted fremanezumab Marketing Authorization in the E.U. for the same indication. In this monograph we review data on the pharmacokinetics, metabolism and safety of fremanezumab as reported in the scientific literature from phase I to phase III studies. Fremanezumab demonstrated a very low incidence of adverse events. Primary and secondary endpoints in randomized, controlled trials on the efficacy of fremanezumab were achieved. Fremanezumab was demonstrated to be able to reduce the number of migraine days, headache hours and number of days with use of acute treatment agents. No data on drug–drug interactions with fremanezumab are available. However, it is worth mentioning that fremanezumab showed a very low incidence of development of adverse drug antibodies compared with other CGRP antibodies.